The transfer of the Cancer Therapy &Research Center (CTRC) and the Cancer Center Support Grant (CCSG) from the CTRC Foundation to the University of Texas Health Science Center at San Antonio (UTHSCSA) in December 2007 was the largest gift in the history of University of Texas (UT) System. A major component of the gift was the entire physical plant of the CTRC, a 330,000 sq. ft. facility dedicated to cancer treatment and research with a focus on clinical research. This physical location is the recognized home of the CTRC and is well recognized by the public as "The Cancer Center." The CTRC physical plant is composed of three buildings which house the multi-disciplinary outpatient clinics and conventional and research infusions suites, a pharmacy. Radiation Oncology facilities the Clinical Trials Office (CTO), conference rooms, two research laboratories and the Administrative Offices of the CTRC . Since the integration of the CTRC into the UTHSCSA, the UTHSCSA has opened a new research building, the South Texas Research Facility (STRF), located adjacent to the CTRC building. The STRF, a 190,000 sq.ft. building containing both office space and wet laboratories, opened in October 2012. The UTHSCSA allocated 25,000 sq. ft. of the STRF's research laboratories to the CTRC adding to the CTRC's research space. The CTRC Director has authority to assign all CTRC-designated space (as listed in Table 1). Should an investigator leave the CTRC, any vacated CTRC-designated space reverts back to the CTRC. Additional space (-38,0000 sq. ft.) in various departments of the UTHSCSA is used for cancer research but is under the control of the respective Department Chairs in collaboration with the CTRC Director. When new recruits with a cancer focus are identified, space for the investigator's cancer research is negotiated in consultation with the CTRC Director. In many cases, the CTRC provides support for the start-up package and the departments provide the space. In some cases, the opposite is true and the CTRC provides space while the department contributes to the startup package.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758449
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$177,835
Indirect Cost
$13,244
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014
Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185
Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289
Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82
Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10
Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190

Showing the most recent 10 out of 853 publications